SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003; 361: 1320.
  • 2
    Zhu MM, Feit A, Chadow H, et al. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol 2001; 88: 297301.
  • 3
    Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 13151323.
  • 4
    Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimuseluting stents with bare-metal stents. N Engl J Med 2007; 356: 10301039.
  • 5
    Melfi R, Nusca A, Patti G, et al. The risks and benefits of drug-eluting stents in the setting of STEMI. Curr Cardiol Rep 2008; 10: 402406.
  • 6
    Schomig A, Dibra A, Windecker S, et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 13731380.
  • 7
    Lee JH, Kim HS, Lee SW, et al. Prospective randomized comparison of sirolimus-versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: pROSIT trial. Catheter Cardiovasc Interv 2008; 72: 2532.
  • 8
    Kim HS, Lee JH, Lee SW, et al. Long-term safety and efficacy of sirolimus-vs. paclitaxel-eluting stent implantation for acute ST-elevation myocardial infarction: 3-year follow-up of the PROSIT trial [published online ahead of print September 25, 2009]. Int J Cardiol. doi:10.1016/j.ijcard.2009.09.466.
  • 9
    Juwana YB, Suryapranata H, Ottervanger JP, et al. Comparison of rapamycin- and paclitaxel-eluting stents in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. Am J Cardiol 2009; 104: 205209.
  • 10
    Di Lorenzo E, Sauro R, Varricchio A, et al. Long-term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial. Circulation 2009; 120: 964972.
  • 11
    Lee CW, Park DW, Lee SH, et al; ZEST-AMI Investigators. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. Am J Cardiol 2009; 104: 13701376.
  • 12
    Cardiosource. American College of Cardiology Web site. ZEST-AMI. http://www.cardiosource.com/clinicaltrials/trial.asp?trialID=1755. Accessed October 30, 2008.
  • 13
    Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629634.
  • 14
    Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 2005; 294: 819825.
  • 15
    Kim YH, Park SW, Lee SW, et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 2006; 114: 21482153.
  • 16
    Lee SW, Park SW, Kim YH, et al. A randomized comparison of sirolimus-versus paclitaxel-eluting stent implantation in patients with diabetes mellitus 2-year clinical outcomes of the DES-DIABETES trial. J Am Coll Cardiol 2009; 53: 812813.
  • 17
    Shuchman M. Trading restenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med 2006; 355: 19491952.
  • 18
    Wijns WC, Krucoff MW. Increased mortality after implantation of first generation drug-eluting stents: seeing the smoke, where is the fire? Eur Heart J 2006; 27: 27372739.
  • 19
    Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006; 98: 352356.
  • 20
    Pinto Slottow TL, Steinberg DH, Roy PK, et al. Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. Am J Cardiol 2008; 102: 298303.
  • 21
    Piscione F, Piccolo R, Cassese S, et al. Effect of drug-eluting stents in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis of randomised trials and an adjusted indirect comparison. EuroIntervention 2010; 5: 853860.
  • 22
    Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193202.
  • 23
    Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus-or paclitaxel-eluting stents. Circulation 2005; 112: 270278.
  • 24
    Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 10201029.
  • 25
    Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 23122317.